Icosapent ethyl (Eicosapentaenoic acid ethyl ester): Effects upon high-sensitivity C-Reactive protein and lipid parameters in patients with metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 6, 2015, Pages 239-247

  Bays, Harold E ^a   Ballantyne, Christie M ^b   Braeckman, Rene A ^c   Stirtan, William G ^d   Doyle, Ralph T ^d   Philip, Sephy ^d,e   Soni, Paresh N ^c   Juliano, Rebecca A ^d  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Amarin Pharma Inc ^*  (United States)

^d Amarin Pharma Inc   (United States)

^e Department of Interventional Cardiology Chilton Memorial Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; AUTACOID; BIOLOGICAL MARKER; ICOSAPENTAENOIC ACID; LIPID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; METABOLISM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; LIPIDS; METABOLIC SYNDROME X; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937564369     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0137     Document Type: Article

References (53)

1. Bays H. Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. Curr Atheroscler Rep 2014; 16:409.
2. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011; 57:2461-2473.
3. Bays H. Central obesity as a clinical marker of adiposo-pathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21:345-351.
4. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
5. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
6. Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7:304-383.
7. Yang J, Kang J, Guan Y. The mechanisms linking adiposopathy to type 2 diabetes. Front Med 2013; 7:433-144.
8. Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: Treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol 2012; 110:4B-12B.
9. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28:629-636.
10. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6:343-368.
11. Bays H, Ballantyne C. Adiposopathy: Why do adiposity and obesity cause metabolic disease? Future Lipidol 2006; 1:389-420.
12. de Voorde JV, Boydens C, Pauwels B, et al. Perivascular adipose tissue, inflammation and vascular dysfunction in obesity. Curr Vasc Pharmacol 2014; 12:403-411.
13. Ridker PM, Kastelein JJ, Genest J, et al. C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. Eur Heart J 2013; 34:1258-1261.
14. Kaptoge S, Di AE, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367:1310-1320.
15. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197:12-24.
16. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106:2747-2757.
17. Silva V, Barazzoni R, Singer P. Biomarkers of fish oil omega-3 polyunsaturated fatty acids intake in humans. Nutr Clin Pract 2014; 29:63-72.
18. Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008; 6:391-409.
19. Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholi-pase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011; 5:483-492.
20. Chan DC, Watts GF, Barrett PH, et al. Effect ofatorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002; 48:877-883.
21. Bloomer RJ, Larson DE, Fisher-Wellman KH, et al. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study. Lipids Health Dis 2009; 8:36.
22. Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose- response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011; 93:243-252.
23. Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013; 13: 37-46.
24. Satoh N, Shimatsu A, Kotani K, et al. Highly purified ei-cosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 2009; 32:1004-1008.
25. Watanabe E, Sobue Y, Sano K, et al. Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. Ann Noninvasive Electrocardiol 2011; 16:373-378.
26. Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc., 2013.
27. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosa-pentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682-690.
28. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high tri- glycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984-992.
29. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014; 105:141-150.
30. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-de-ficient mice. Circulation 2004; 109:647-655.
31. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-515.
32. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
33. Zhang D, Che D, Zhao S, et al. Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholes-terolemic rabbits. J Cardiovasc Pharmacol 2007; 50:281-285.
34. Zhao SP, Zhang DQ. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hyper-cholesterolemic rabbits. Clin Chim Acta 2003; 336:103-108.
35. Ciubotaru I, Lee YS, Wander RC. Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT. JNutr Biochem 2003; 14:513-521.
36. Madsen T, Christensen JH, Blom M, et al. The effect of dietary n-3 fatty acids on serum concentrations of C-reac-tive protein: A dose-response study. Br J Nutr 2003; 89: 517-522.
37. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosa-pentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003; 35: 772-781.
38. Geelen A, Brouwer IA, Schouten EG, et al. Intake of n-3 fatty acids from fish does not lower serum concentrations of C-reactive protein in healthy subjects. Eur J Clin Nutr 2004; 58:1440-1442.
39. Sundrarjun T, Komindr S, Archararit N, et al. Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. J Int Med Res 2004; 32:443-454.
40. Sanders TA, Gleason K, Griffin B, et al. Influence of an algal triacylglycerol containing docosahexaenoic acid (22: 6n-3) and docosapentaenoic acid (22: 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 2006; 95:525-531.
41. Madsen T, Christensen JH, Schmidt EB. C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: A placebo-controlled randomized study. Eur J Nutr 2007; 46:428-430.
42. Murphy KJ, Meyer BJ, Mori TA, et al. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids onerythrocyte n-3 levels and cardiovascular risk factors. Br J Nutr 2007; 97:749-757.
43. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosa-pentaenoic acid reduces small dense LDL, remnant lipo-protein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007; 30:144-146.
44. Tsitouras PD, Gucciardo F, Salbe AD, et al. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm Metab Res 2008; 40:199-205.
45. Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr 2009; 63:1154-1156.
46. Kelley DS, Siegel D, Fedor DM, et al. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 2009; 139:495-501.
47. Kohashi K, Nakagomi A, Saiki Y, et al. Effects of eico-sapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb 2014; 21:712-729.
48. Ebbesson SO, Tejero ME, Nobmann ED, et al. Fatty acid consumption and metabolic syndrome components: The GOCADAN study. J Cardiometab Syndr 2007; 2:244-249.
49. Lopez-Alvarenga JC, Ebbesson SO, Ebbesson LO, et al. Polyunsaturated fatty acids effect on serum triglycerides concentration in the presence of metabolic syndrome components. The Alaska-Siberia Project. Metabolism 2010; 59:86-92.
50. Bays HE, Maki KC, Doyle RT, et al. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. Post-gradMed 2009; 121:145-150.
51. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary. J Clin Lipidol 2014; 8:473-488.
52. Bays HE, Jones PH, Brown WV, et al. National lipid association annual summary of clinical lipidology 2015. J Clin Lipidol 2014; 8:S1-S36.
53. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hyper-triglyceridemia and on statin (REDUCE-IT). Available at http://clinicaltrials.gov/show/NCT01492361/. Accessed January 15, 2015.